Led · Series A · Jul 2025

Robotera builds full-stack humanoid robots combining AI "brain" systems, motion control, dexterous hands and humanoid hardware, and positions itself toward logistics and industrial deployments. The company reports beginning deliveries of several thousand units in Q2 2026 and claims deployments in over ten logistics centers across China with partners including SF Group and China Post. Robotera states it has achieved up to 85% of human efficiency in some logistics contexts operating 24/7 and cites a claimed 300% growth rate (no baseline published). Its investor and partner base spans logistics, automotive and consumer electronics players such as SF Group, Geely, Renault (cited as a partner), Alibaba, Samsung, Lenovo and Haier, which the company and articles present as potential channels for further deployments. Financially, the company has raised nearly ¥2.5 billion RMB (~$350M) in total capital following the recent financing, which the company says supports scaling production and broader commercial rollouts. The articles note competition from Western and Chinese robotics firms but highlight Robotera’s operational logistics focus and industrial partnerships as key differentiators.

Participated · Equity · Mar 2024

PATEO focuses on developing next‑generation intelligent integrated domain control products, including smart cockpits, autonomous‑driving domain controllers, automotive‑grade chips, high‑performance central computing platforms (CCP) and display modules. The company plans to invest proceeds in full‑stack technological innovation, cabin‑driving fusion solutions and building an integrated smart manufacturing and supply chain system across the Yangtze River Delta with Shanghai as its axis, plus planning for a future Lighthouse Factory. It recently secured approximately ¥1.5 billion in new equity financing and signed a ¥19 billion credit and strategic cooperation agreement with seven state‑owned banks. PATEO has invested nearly ¥2 billion in R&D to date and has accumulated 6,692 intellectual property rights, 83% of which are invention patents, ranking first in China’s intelligent automotive connectivity patents. The article notes the company has completed multiple prior equity rounds and attracted strategic investors and industry partners as it expands internationally and wins overseas orders.

Participated · Series B · Aug 2021

Zuoshouyisheng (Beijing Zuoyi Technology Co., Ltd.) builds an AI doctor platform that interprets patient symptoms and generates diagnoses using deep learning and big data. The platform spans 35 medical specialties and the company says it can diagnose more than 6,000 diseases. ZSYS primarily sells its AI-empowered healthcare system via a SaaS model to hospitals, pharmaceutical companies, employers, and insurers. The company positions its product to empower medical practitioners, extend reach to more patients, and give the public improved access to healthcare services. The recent funding is earmarked for research and development of new AI technologies and for commercial applications. No revenue or user metrics are disclosed in the article.

Participated · Series D · Mar 2021

Shanghai Cell Therapy Group, founded in 2013, positions itself as a platform company that closes the loop across new‑drug R&D, tumor clinical treatment and cell preservation services. Its core products and clinical pipeline include the non‑viral vector CD19 CAR‑T injection BZ019, which the company says was the first non‑viral CAR‑T product in China to enter clinical trials; related clinical results were accepted by the Journal for ImmunoTherapy of Cancer. The group has invested in clinical and infrastructure assets, including an 800 million RMB investment to establish the Shanghai Mengchao Oncology Hospital as a Shanghai University‑affiliated hospital and insurance‑covered clinical center. A new international cell production center (1.6万平方米) was scheduled for completion in April 2021 with an announced capacity to prepare CAR‑T cells for up to 20,000 patients annually; additional talent and campus facilities (including a Nobel center and staff apartments) were planned for 2021 completion. The company reports extensive IP and expert engagement, with 217 patents, 193 invention patents, 167 trademarks, collaborations with 32 Nobel laureates and five domestic/international academy members, and partnerships with institutions such as USC and Shanghai University. The company has expanded regionally with multiple provincial cell therapy groups established in 2019–2020. Shanghai Cell Therapy Group focuses on R&D of cellular immunotherapy technologies and develops novel cell therapies while providing large‑scale cell banking and cryopreservation services. The company is building clinical capacity, including the soon‑to‑open Shanghai Wu Mengchao Cancer Hospital, and operates clinical testing that conforms to CFDA, USFDA and JCI standards. It plans a 200‑room production facility, a 3,000 m2 quality control center, and a cell preservation warehouse with capacity for 30 million human samples. Shanghai Cell Therapy Group has pursued an active IP program, applying for 117 patents (25 PCT) with 21 approvals including two U.S. patents. Thirty of its cellular immunotherapy technologies have received clinical ethical approval and 20 have been registered with the National Clinical Trial Institute. The company cites policy support from Shanghai municipal plans and is based in the Jiading medical‑industry district.

Led · Series A · Nov 2017

FutureMove Automotive develops Digital and Mobility products encompassing software, hardware and an operations platform and positions itself as a Digital and Mobility Service Provider with the vision “Smart Vehicle as Service.” The company said proceeds from its A+ round will fund R&D across its product stack and operations. Leadership (CEO and Chairman John Wang) highlighted strategic collaboration opportunities with industrial partners in smart home, intelligent manufacturing, smart logistics and IoT. The company has delivered technology and services to global OEMs, and Photon Fund had been an existing investor from the A round. FutureMove framed the A+ financing as strategically important to deepen its digital and mobility offerings and expand market services. No operating metrics (revenue/users) were disclosed in the article.